首页> 外文期刊>Cytogenetic and genome research >Assessing the Clinical Utility of SNP Microarray for Prader-Willi Syndrome due to Uniparental Disomy
【24h】

Assessing the Clinical Utility of SNP Microarray for Prader-Willi Syndrome due to Uniparental Disomy

机译:评估SNP微阵列为PRADER-WILLI综合征的临床效用因天空发球症体

获取原文
获取原文并翻译 | 示例
       

摘要

Maternal uniparental disomy (UPD) 15 is one of the molecular causes of Prader-Willi syndrome (PWS), a multisystem disorder which presents with neonatal hypotonia and feeding difficulty. Current diagnostic algorithms differ regarding the use of SNP microarray to detect PWS. We retrospectively examined the frequency with which SNP microarray could identify regions of homozygosity (ROH) in patients with PWS. We determined that 7/12 (58%) patients with previously confirmed PWS by methylation analysis and microsatellite-positive UPD studies had ROH(>10 Mb) by SNP microarray. Additional assessment of 5,000 clinical microarrays, performed from 2013 to present, determined that only a single case of ROH for chromosome 15 was not caused by an imprinting disorder or identity by descent. We observed that ROH for chromosome 15 is rarely incidental and strongly associated with hypotonic infants having features of PWS. Although UPD microsatellite studies remain essential to definitively establish the presence of UPD, SNP microarray has important utility in the timely diagnostic algorithm for PWS. (C) 2017 S. Karger AG, Basel
机译:孕产妇发单人强性(UPD)15是PRADER-WILLI综合征(PWS)的分子原因之一,是具有新生儿肺炎和喂养困难的多系统障碍。目前的诊断算法因使用SNP微阵列来检测PWS而异。我们回顾性地检查了SNP微阵列可以识别PWS患者纯合理区域(ROH)区域的频率。我们确定7/12(58%)通过甲基化分析和微卫星 - 阳性更新研究的先前证实的PWs患者通过SNP微阵列具有RoH(> 10MB)。从2013年开始的5,000个临床微阵列的额外评估确定,仅确定染色体15的单一案例rOH不是由下降印迹疾病或身份引起的。我们观察到染色体15的ROH很少有偶然偶然,与具有PWS的特征的低渗婴儿有关。虽然UPD微卫星研究仍然是必不可少的,但明确地建立更新的存在,但SNP MicroArray在适当的PWS诊断算法中具有重要的实用性。 (c)2017年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号